The Latest Breaking News from Gilead

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

The drugmaker said its injections were 89 percent more effective than its own Truvada

A study shows that a twice-yearly shot was 100% effective in preventing new HIV infections in women in Africa

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Support for Gilead shares sits near 57.

Gilead stock surged Thursday after its twice-annual shot proved 100% effective in preventing HIV infections in cisgender women.

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

Gilead stock reversed lower Monday after confirming it's testing a popular weight-loss mechanism as a treatment for a liver disease.